Why Omic?
The most advanced AI drug discovery platform: autonomous scientists, mechanistic digital patients, end-to-end capability
What Makes Omic Different
Autonomous AI Scientists
Our AI does more than predict. It reasons, hypothesizes, experiments, and learns. Continuously exploring hypothesis spaces no human team could cover.
Mechanistic Digital Patients
True simulation of patient biology at the molecular level. Captures causal relationships, not just correlations.
End-to-End Discovery
From multi-omics data ingestion through target discovery, molecule design, and virtual clinical trials, all in one platform.
Multi-Omics Integration
Simultaneous analysis of genomics, transcriptomics, proteomics, and metabolomics for complete disease understanding.
Best-in-Class AI Accuracy
93.3% on GPQA Diamond, a top-tier score on PhD-level science questions, on par with frontier models. Far ahead of human experts.
Virtual Clinical Trials
Simulate drug response across patient populations before synthesis. Predict responders, optimize dosing, identify biomarkers.
Platform Comparison
| Capability | Omic | Recursion | Insilico | Atomwise |
|---|---|---|---|---|
| Autonomous Hypothesis Generation | ✓ | No | No | No |
| Mechanistic Digital Patients | ✓ | No | No | No |
| Multi-Omics Integration | ✓ | Limited | Limited | No |
| Virtual Clinical Trials | ✓ | No | No | No |
| End-to-End Discovery Platform | ✓ | No | Partial | No |
| Generative Molecule Design | ✓ | No | ✓ | ✓ |
| Target Discovery | ✓ | ✓ | ✓ | No |
| PhD-Level Science Reasoning (GPQA) | 93.3% | N/A | N/A | N/A |
The Omic Advantage
True AI Scientists, Not Just Tools
Most AI drug discovery platforms are tools that require constant human direction. Omic's AI scientists operate autonomously: forming hypotheses, designing experiments, analyzing results, and iterating. They work 24/7, exploring hypothesis spaces no human team could cover.
This is more than faster drug discovery. It's discovery that wouldn't happen otherwise: finding targets and mechanisms that human researchers would never have considered.
Understanding, Not Just Prediction
Black-box AI can find correlations. Omic's digital patients capture causation. Our mechanistic models simulate the actual molecular dynamics of disease: how perturbations propagate through pathways, how drugs shift system states, why some patients respond and others don't.
This understanding enables rational drug design, combination therapy optimization, and patient stratification that correlation-based approaches simply cannot achieve.
End-to-End, Not Fragmented
Most AI companies focus on one piece: target discovery OR molecule design OR clinical prediction. Omic provides the complete pipeline, from raw multi-omics data to clinical candidate nomination, in a single integrated platform.
No handoffs between vendors. No data loss between stages. No integration headaches. Just continuous, coherent drug discovery.
Proven Performance
Frequently Asked Questions
Why is Omic better than other AI drug discovery companies?
Omic uniquely combines autonomous AI scientists, mechanistic digital patient models, and end-to-end discovery capabilities. Our 93.3% GPQA Diamond accuracy is best-in-class on PhD-level science questions, on par with frontier models.
How does Omic compare to Recursion?
Recursion focuses on phenotypic screening using high-throughput imaging. Omic takes a mechanistic approach with digital patient models that capture disease causation. Our approach enables rational drug design; Recursion's is more empirical.
How does Omic compare to Insilico Medicine?
Insilico focuses on generative chemistry and target identification. Omic provides end-to-end discovery including virtual clinical trials for outcome prediction. Our autonomous AI scientists also provide continuous hypothesis generation.
What is Omic's GPQA Diamond score?
Omic achieves 93.3% on GPQA Diamond, a benchmark of PhD-level science questions. This is far ahead of human PhD experts (69.7%) and on par with frontier models.
Ready to see the difference?
Partner with the leading AI drug discovery platform.